A Randomized, Double-Blind, Placebo-Controlled Multicenter Study of Adalimumab in Pediatric Patients With Enthesitis-Related Arthritis.

Change from baseline in SJC, TJC, and enthesitis count did not reach statistical significance due to low baseline values in some patients, making change more difficult to detect; however, more than 80% of patients treated with adalimumab had complete resolution of swollen joints, tender joints, or enthesitis (achieved SJC, TJC, or enthesitis count of 0) by week 52, with SJC improving faster than TJC or enthesitis count.

also in 111,027 other papers